JPWO2023154734A5 - - Google Patents

Info

Publication number
JPWO2023154734A5
JPWO2023154734A5 JP2024545925A JP2024545925A JPWO2023154734A5 JP WO2023154734 A5 JPWO2023154734 A5 JP WO2023154734A5 JP 2024545925 A JP2024545925 A JP 2024545925A JP 2024545925 A JP2024545925 A JP 2024545925A JP WO2023154734 A5 JPWO2023154734 A5 JP WO2023154734A5
Authority
JP
Japan
Prior art keywords
rna polynucleotide
utr
composition
rna
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505576A5 (https=
JP2025505576A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062194 external-priority patent/WO2023154734A2/en
Publication of JP2025505576A publication Critical patent/JP2025505576A/ja
Publication of JPWO2023154734A5 publication Critical patent/JPWO2023154734A5/ja
Publication of JP2025505576A5 publication Critical patent/JP2025505576A5/ja
Pending legal-status Critical Current

Links

JP2024545925A 2022-02-08 2023-02-08 mRNAの発現及び送達システム Pending JP2025505576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267703P 2022-02-08 2022-02-08
US63/267,703 2022-02-08
PCT/US2023/062194 WO2023154734A2 (en) 2022-02-08 2023-02-08 Mrna expression and delivery systems

Publications (3)

Publication Number Publication Date
JP2025505576A JP2025505576A (ja) 2025-02-28
JPWO2023154734A5 true JPWO2023154734A5 (https=) 2026-02-04
JP2025505576A5 JP2025505576A5 (https=) 2026-02-04

Family

ID=87565058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545925A Pending JP2025505576A (ja) 2022-02-08 2023-02-08 mRNAの発現及び送達システム

Country Status (7)

Country Link
US (1) US20250236645A1 (https=)
EP (1) EP4476252A4 (https=)
JP (1) JP2025505576A (https=)
CN (1) CN118715326A (https=)
AU (1) AU2023219116A1 (https=)
CA (1) CA3250246A1 (https=)
WO (1) WO2023154734A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119876129A (zh) * 2024-08-16 2025-04-25 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) 一种启动子元件及对植物进行基因编辑的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428886B1 (de) * 2002-12-09 2009-08-05 Celltech GmbH Biotechnologie Verbesserte retrovirale Vektoren für die Gentherapie
US20080171361A1 (en) * 2007-01-11 2008-07-17 The Board Of Regents For Oklahoma State University CAP-Independent Translational Enhancer for Protein Synthesis in Wheat Germ Extract and Transgenic Cereals
US9534234B2 (en) * 2014-04-09 2017-01-03 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
EP3551230A1 (en) * 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
CN109971775B (zh) * 2017-12-27 2021-12-28 康码(上海)生物科技有限公司 一种核酸构建物及其调控蛋白合成的方法
FR3081169B1 (fr) * 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
US12264323B2 (en) * 2018-12-17 2025-04-01 The Broad Institute, Inc. CRISPR CPF1 direct repeat variants
IL296617A (en) * 2020-03-20 2022-11-01 Biontech Us Inc Vaccines against the corona virus and methods of use
EP4277641A4 (en) * 2021-02-26 2025-03-19 Duke University Compositions for and methods of improving gene therapy

Similar Documents

Publication Publication Date Title
Zong et al. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy
US20260091101A1 (en) Bunyavirales vaccine
JP7523897B2 (ja) 呼吸器合胞体ウイルス(rsv)ワクチン
JP6827488B2 (ja) 鼻内送達のための方法および組成物
JP7105193B2 (ja) トランス複製型rna
Minigo et al. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy
EP2772251B1 (en) Protamine/RNA nanoparticles for immunostimulation
EP1513552B1 (en) Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use
JP2022539105A (ja) 治療に好適なrna製剤
JP2021519595A (ja) 新規rsv rna分子及びワクチン接種用組成物
Yu et al. The clinical progress and challenges of mRNA vaccines
WO2023104114A2 (en) Rna formulations and lipids
WO2023172547A1 (en) Nucleic acid-lipid nanoparticle and method using the same
CN112294954B (zh) 一种禽用佐剂组合物及其制备方法和应用
JPWO2023154734A5 (https=)
JP2023012539A (ja) 経鼻b型肝炎ワクチン組成物およびその製造方法
JP2023536844A (ja) ワクチン接種を改善するための組成物および方法
WO2024120490A1 (en) Self-replicating rna vaccines and methods of use
CN118576725A (zh) 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用
JP2002510496A (ja) 細胞傷害性t細胞を誘導するための医薬
Zhou et al. Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly
WO2023109961A1 (en) Interleukin-12 self-replicating rna and methods
CN104189922B (zh) 一种载新城疫DNA疫苗Ag@SiO2纳米粒的制备方法
WO2025038868A1 (en) Lipid nanoparticle formulations and uses thereof
Chavda et al. mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown! Vaccines 2023, 11, 507